<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00401128</url>
  </required_header>
  <id_info>
    <org_study_id>CASE-CCF-6695</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE-CCF-6695</secondary_id>
    <nct_id>NCT00401128</nct_id>
  </id_info>
  <brief_title>Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer</brief_title>
  <official_title>Phase II Study of Gemcitabine Plus Irinotecan in Patients With Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine and irinotecan, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects and how well giving gemcitabine&#xD;
      together with irinotecan works in treating patients with metastatic kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate in patients with epithelial (clear or nonclear cell) renal&#xD;
           cell carcinoma (RCC) treated with gemcitabine hydrochloride and irinotecan&#xD;
           hydrochloride.&#xD;
&#xD;
        -  Compare the response in patients with clear cell RCC vs nonclear cell RCC treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine the toxicities of this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label study.&#xD;
&#xD;
      Patients receive gemcitabine hydrochloride IV over 30 minutes and irinotecan hydrochloride IV&#xD;
      over 90 minutes on days 1 and 8. Treatment repeats every 21 days for at least 6 courses in&#xD;
      the absence of unacceptable toxicity or disease progression.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and efficacy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in response to therapy in patients with clear vs nonclear cell renal cell carcinoma</measure>
  </secondary_outcome>
  <enrollment type="Actual">9</enrollment>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed epithelial renal cell carcinoma (RCC),&#xD;
             including either clear cell or nonclear cell RCC&#xD;
&#xD;
          -  Strong clinical evidence or biopsy proof of metastases to a site or sites distant from&#xD;
             the primary tumor&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No untreated or progressive CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm³&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin &gt; 9.5 g/dL&#xD;
&#xD;
          -  Creatinine ≤ 1.8 mg/dL&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 mg/dL&#xD;
&#xD;
          -  Calcium &lt; 11.5 mg/dL&#xD;
&#xD;
          -  ALT and AST &lt; 3 times upper limit of normal&#xD;
&#xD;
          -  No history of any of the following:&#xD;
&#xD;
               -  Serious cardiac arrhythmia or cardiac arrhythmia requiring treatment&#xD;
&#xD;
               -  Congestive heart failure&#xD;
&#xD;
               -  Angina pectoris&#xD;
&#xD;
               -  Other severe cardiovascular disease producing limitations of physical activity&#xD;
                  (i.e., New York Heart Association class III-IV heart disease)&#xD;
&#xD;
          -  No other prior malignancy except for the following:&#xD;
&#xD;
               -  Basal cell or squamous cell carcinoma of the skin&#xD;
&#xD;
               -  Carcinoma in situ of the uterine cervix&#xD;
&#xD;
               -  Any malignancy treated with curative intent and in complete remission for &gt; 3&#xD;
                  years&#xD;
&#xD;
          -  No active peptic ulcer disease, inflammatory bowel disease, or chronic diarrhea&#xD;
&#xD;
          -  No local or systemic infections requiring IV antibiotics within the past 28 days&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Recovered from prior hormonal therapy, radiotherapy, biologic therapy, or chemotherapy&#xD;
&#xD;
          -  No more than 3 prior therapeutic regimens for metastatic disease&#xD;
&#xD;
          -  No prior organ allograft&#xD;
&#xD;
          -  More than 28 days since prior major surgery requiring general anesthesia&#xD;
&#xD;
          -  More than 28 days since prior radiotherapy to control pain from skeletal lesions&#xD;
&#xD;
          -  More than 28 days since prior hormonal treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald M. Bukowski, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>November 16, 2006</study_first_submitted>
  <study_first_submitted_qc>November 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2006</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>clear cell renal cell carcinoma</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>papillary renal cell carcinoma</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

